Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSemaglutide has a half-life of roughly seven days, which means it takes around five weeks for the medicine to clear your system after your final injection. That figure applies whether you have been taking Wegovy for weight management or Ozempic for type 2 diabetes. A half-life of seven days means that, each week after stopping, approximately half the remaining concentration is eliminated — so after five half-lives (five weeks) most of the drug has gone, though trace amounts may persist a little longer. These are prescription-only medicines, and how your body responds during and after stopping is something to discuss with your prescriber rather than manage alone. The NHS semaglutide medicines page covers the pharmacology in accessible terms, and the full detail is in the patient information leaflet that comes with your treatment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
You've decided to stop, or you're wondering what would happen if you did. Either way, you want a straight answer rather than a vague "it depends". Here it is: semaglutide's elimination half-life sits at roughly seven days in adults. That is a relatively long half-life compared to most medicines, which is exactly why Wegovy works as a once-weekly injection in the first place, steady concentrations, no daily peaks and troughs.
After your final dose, concentrations roughly halve each week. By week three, you are down to about 12.5% of peak levels. By week five, traces are below 3% of what was circulating at steady state. Clinically, most prescribers consider five weeks the practical clearance window, and if you want to understand how long it takes for semaglutide to get out of your system in more detail, that page breaks down the week-by-week picture. Trace amounts beyond that are unlikely to be pharmacologically active for most people.
The pace of clearance is broadly similar regardless of which maintenance dose you were on, because the half-life is a property of the molecule itself, not the quantity injected. If you want to understand how long Wegovy stays in your system at different stages of treatment, that page walks through the steady-state concentrations that build over the first few months too.
This is usually what people are actually asking. The pharmacokinetics tell you when the drug is gone; the experience of your appetite returning is a slightly different question.
Semaglutide slows gastric emptying and acts on appetite centres in the brain via GLP-1 receptors. As concentrations fall after stopping, those signals weaken. Most people notice hunger returning within one to two weeks of their last injection. For some it is sooner; a minority describe a more gradual shift. By around four weeks, the subjective appetite suppression is generally gone.
What follows that is the part worth being honest about. Clinical trials including STEP 1, published in the New England Journal of Medicine, followed participants after stopping semaglutide and found that weight regain began relatively quickly once the drug was out of the system and lifestyle support was reduced. Around two-thirds of lost weight was regained within a year of stopping in that extension cohort. That is not a reason to feel defeated, it reflects the biology of obesity, not a character flaw. It does explain why clinical guidance increasingly frames these medicines as long-term treatments rather than short courses. If you are weighing up whether to continue or stop, a conversation with a prescriber is more useful than a self-managed taper. Our Wegovy expected weight loss page puts the trial evidence into plain context.
Knowing the clearance window matters for a few specific situations beyond simple curiosity.
If you are planning a surgical procedure, NHS England guidance is clear: tell your anaesthetist and surgical team that you have been on a GLP-1 medicine. Some anaesthetists request a pause before general anaesthesia because of the gastric-emptying effects, the exact period they ask for varies, so follow their instruction rather than a generic online figure.
Pregnancy is a harder line. Semaglutide is not recommended during pregnancy, breastfeeding, or when actively trying to conceive. The MHRA advises using effective contraception while on treatment and for a washout period after stopping before attempting conception. If you are trying to work out how long before semaglutide is out of your system ahead of planning a pregnancy, five weeks aligns with the pharmacokinetic clearance, but your prescriber or GP should advise on the specific timing for your circumstances.
If you are thinking about switching from Wegovy to another weight management treatment, the five-week clearance window is relevant to prescribers assessing overlap. People who have been asking themselves how long till Wegovy is out of your system ahead of a switch will find that our page on how long Wegovy is out of your system covers the week-by-week picture in more detail, though it is always worth bringing that question to your prescriber directly. For context on what other licensed options look like, our weight loss treatments overview covers what is currently available in the UK and how they differ.
If you have questions about how Wegovy fits your specific situation, or you are weighing whether treatment is right for you in the first place, start a free consultation with our prescribers. There is no obligation, and your answers are reviewed by a real clinician on the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.